AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma

Summary

This phase II trial is studying how well AZD2171 works in treating patients with recurrent or stage IV melanoma. AZD2171 may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.

Timeline

Start

2006-01

Primary completion

2012-03

Completion

2012-03

Drugs

Indications